{"nctId":"NCT01217944","briefTitle":"Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","startDateStruct":{"date":"2010-10"},"conditions":["Pathological Myopia"],"count":277,"armGroups":[{"label":"Ranibizumab driven by disease activity","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab","Drug: Sham Ranibizumab","Drug: Sham verteporfin PDT"]},{"label":"Ranibizumab driven by stabilization criteria","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab","Drug: Sham Ranibizumab","Drug: Sham verteporfin PDT"]},{"label":"Verteporfin PDT","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab","Drug: Verteporfin PDT","Drug: Sham Ranibizumab","Drug: Sham verteporfin PDT"]}],"interventions":[{"name":"Ranibizumab","otherNames":[]},{"name":"Verteporfin PDT","otherNames":["vPDT"]},{"name":"Sham Ranibizumab","otherNames":[]},{"name":"Sham verteporfin PDT","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Visual impairment due to choroidal neovascularization (CNV) secondary to PM\n* Best corrected visual acuity (BCVA) in the study eye \\> 24 and \\< 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters\n* High myopia (\\> -6D), anterior-posterior elongation \\> 26 mm; posterior changes compatible with the pathologic myopia\n* Either lesion types in the study eye: subfoveal, juxtafoveal, extrafoveal\n\nExclusion Criteria:\n\n* Patients with uncontrolled systemic or ocular diseases\n* Blood pressure \\> 150/90 mmHg\n* History of pan-retinal, focal/grid laser photocoagulation or intraocular treatment with any anti-VEGF or vPDT in the study eye\n* Intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye","description":"The Best Corrected Visual Acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts at baseline and compared to the average from month 1 to month 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":"13.43"},{"groupId":"OG001","value":"55.8","spread":"12.59"},{"groupId":"OG002","value":"54.7","spread":"13.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":"12.98"},{"groupId":"OG001","value":"66.4","spread":"12.28"},{"groupId":"OG002","value":"56.9","spread":"14.49"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline to Month 6 in Visual Acuity of the Study Eye","description":"The Best Corrected Visual Acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts at baseline and month 6. The overall BCVA score was calculated using the BCVA worksheet.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":"13.43"},{"groupId":"OG001","value":"55.8","spread":"12.59"},{"groupId":"OG002","value":"54.7","spread":"13.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":"12.44"},{"groupId":"OG001","value":"68.4","spread":"13.56"},{"groupId":"OG002","value":"62.7","spread":"14.65"}]}]}]},{"type":"SECONDARY","title":"Average Change From Baseline to Month 1 Through Month 12 in Visual Acuity of the Study Eye","description":"The Best Corrected Visual Acuity (BCVA) was tested using the Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity (VA) testing protocol. VA measurements were taken in a sitting position at an initial test distance of 4 meters using ETDRS charts at baseline and Month 1 through 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":"13.43"},{"groupId":"OG001","value":"55.8","spread":"12.59"},{"groupId":"OG002","value":"54.7","spread":"13.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":"12.61"},{"groupId":"OG001","value":"68.3","spread":"12.45"},{"groupId":"OG002","value":"61.1","spread":"14.86"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Best Corrected Visual Acuity (BCVA) ≥10 and ≥15 Letters Gain or Reach 84 Letters at Month 3","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained more than 10 or more than 15 of visual acuity at month 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":null},{"groupId":"OG001","value":"43.1","spread":null},{"groupId":"OG002","value":"14.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.9","spread":null},{"groupId":"OG001","value":"65.5","spread":null},{"groupId":"OG002","value":"27.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Best Corrected Visual Acuity (BCVA) ≥10 and ≥15 Letters Gain or Reach 84 Letters at Month 6 and Month 12","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained more than 10 or more than 15 letters of visual acuity at month 6 and month 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"44.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"51.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null},{"groupId":"OG001","value":"69.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Best Corrected Visual Acuity (BCVA) ≥10 and ≥15 Letter Loss at Month 3","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. A decreased score indicates worsening in acuity. This outcome assessed the percentage of participants who lost more than 10 or more than 15 of visual acuity at month 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"16.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Best Corrected Visual Acuity (BCVA) ≥10 and ≥15 Letter Loss at Month 6 and 12","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. A decreased score indicates worsening in acuity. This outcome assessed the percentage of participants who lost more than 10 or more than 15 of visual acuity at month 6 and 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Retinal Thickness of the Study Eye Over Time","description":"Retinal thickness was measured by Central Reading Center using patient's Optical Coherence Tomography (OCT) images provided by investigators.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"349.2","spread":"95.05"},{"groupId":"OG001","value":"373.1","spread":"127.44"},{"groupId":"OG002","value":"352.5","spread":"101.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"288.3","spread":"70.14"},{"groupId":"OG001","value":"295.6","spread":"71.93"},{"groupId":"OG002","value":"340.5","spread":"106.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"283.1","spread":"67.43"},{"groupId":"OG001","value":"298.3","spread":"81.16"},{"groupId":"OG002","value":"303.5","spread":"76.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282.6","spread":"68.62"},{"groupId":"OG001","value":"301.8","spread":"88.16"},{"groupId":"OG002","value":"294.3","spread":"83.25"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Choroidal Neovascularization (CNV) Leakage in the Study Eye","description":"CNV leakage assessment plus other choroid and retinal disorders were assessed by Central Reading Center using patient's fluorescein angiography and color fundus photography images provided by investigators.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null},{"groupId":"OG001","value":"93.1","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"6.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null},{"groupId":"OG001","value":"19.0","spread":null},{"groupId":"OG002","value":"29.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"69.8","spread":null},{"groupId":"OG002","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"11.2","spread":null},{"groupId":"OG002","value":"3.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Ranibizumab Injections Received Prior to Month 3","description":"In order to describe exposure to the study drug the number of ejections was evaluated","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"0.57"},{"groupId":"OG001","value":"1.8","spread":"0.82"},{"groupId":"OG002","value":"0.0","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Number of Ranibizumab Injections Received by Patients Randomized to the Ranibizumab Groups, by Period","description":"Number of ranibizumab injections received by patients randomized to the ranibizumab groups, by period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"1.46"},{"groupId":"OG001","value":"2.5","spread":"1.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"2.59"},{"groupId":"OG001","value":"3.5","spread":"2.92"}]}]}]},{"type":"SECONDARY","title":"Number of Ranibizumab Injections Received by Patients Randomized to vPDT With Ranibizumab From Month 3 by Period","description":"Number of ranibizumab injections received by patients randomized to the vPDT with ranibizumab groups, by period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.54"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":106},"commonTop":["Nasopharyngitis","Conjunctival haemorrhage (Study eye)","Headache","Intraocular pressure increased (Study eye)","Punctate keratitis (Study eye)"]}}}